These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6397562)

  • 1. The formation of LDL: mechanisms and regulation.
    Havel RJ
    J Lipid Res; 1984 Dec; 25(13):1570-6. PubMed ID: 6397562
    [No Abstract]   [Full Text] [Related]  

  • 2. Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies.
    Millar JS; Packard CJ
    Curr Opin Lipidol; 1998 Jun; 9(3):197-202. PubMed ID: 9645501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study.
    Cummings MH; Watts GF; Umpleby M; Hennessy TR; Quiney JR; Sönksen PH
    Atherosclerosis; 1995 Feb; 113(1):79-89. PubMed ID: 7755658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the binding and degradation of human very-low-density lipoproteins by human hepatoma cell line HepG2.
    Dashti N; Wolfbauer G
    Biochim Biophys Acta; 1986 Feb; 875(3):473-86. PubMed ID: 3004589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic heterogeneity in very low-density lipoproteins.
    Shepherd J; Packard CJ
    Am Heart J; 1987 Feb; 113(2 Pt 2):503-8. PubMed ID: 3812208
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.
    Boren J; Lee I; Zhu W; Arnold K; Taylor S; Innerarity TL
    J Clin Invest; 1998 Mar; 101(5):1084-93. PubMed ID: 9486979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How does mutant proprotein convertase neural apoptosis-regulated convertase 1 induce autosomal dominant hypercholesterolemia?
    Jirholt P; Adiels M; Borén J
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1334-6. PubMed ID: 15297286
    [No Abstract]   [Full Text] [Related]  

  • 8. Causes of high blood cholesterol.
    Grundy SM; Vega GL
    Circulation; 1990 Feb; 81(2):412-27. PubMed ID: 2404630
    [No Abstract]   [Full Text] [Related]  

  • 9. The uptake of chylomicron remnants by the liver.
    Windler EE
    Adv Exp Med Biol; 1987; 210():131-5. PubMed ID: 3591544
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipoprotein metabolism in familial hypercholesterolemia.
    Shepherd J; Packard CJ
    Arteriosclerosis; 1989; 9(1 Suppl):I39-42. PubMed ID: 2912431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells.
    Ji ZS; Brecht WJ; Miranda RD; Hussain MM; Innerarity TL; Mahley RW
    J Biol Chem; 1993 May; 268(14):10160-7. PubMed ID: 7683668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein B and lipoprotein metabolism.
    Sparks JD; Sparks CE
    Adv Lipid Res; 1985; 21():1-46. PubMed ID: 3895843
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia.
    Teng B; Sniderman AD; Soutar AK; Thompson GR
    J Clin Invest; 1986 Mar; 77(3):663-72. PubMed ID: 3949973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shifting the LDL-receptor paradigm in familial hypercholesterolemia: novel insights from recent kinetic studies of apolipoprotein B-100 metabolism.
    Barrett PH; Watts GF
    Atheroscler Suppl; 2002 Mar; 2(3):1-4. PubMed ID: 11923121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
    Ouguerram K; Chetiveaux M; Zair Y; Costet P; Abifadel M; Varret M; Boileau C; Magot T; Krempf M
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm.
    Fisher WR; Zech LA; Stacpoole PW
    Arterioscler Thromb; 1994 Apr; 14(4):501-10. PubMed ID: 8148348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertriglyceridemia: lipoprotein receptors and atherosclerosis.
    Gianturco SH; Gotto AM; Bradley WA
    Adv Exp Med Biol; 1985; 183():47-71. PubMed ID: 4036704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein B metabolism in man.
    Shepherd J; Packard CJ
    Acta Med Scand Suppl; 1987; 715():61-6. PubMed ID: 3473916
    [No Abstract]   [Full Text] [Related]  

  • 20. Atherogenic lipoproteins resulting from genetic defects of apolipoproteins B and E.
    Weisgraber KH; Innerarity TL; Rall SC; Mahley RW
    Ann N Y Acad Sci; 1990; 598():37-48. PubMed ID: 2248450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.